Disease-free survival is a “surrogate end point”, a measure of a drug’s efficacy that can be used as an alternative to overall survival when testing new treatments. Researchers analyze how long the drug prevents the disease from returning or how long a tumor is prevented from growing, thereby accelerating trials and bringing drugs to market more quickly than if using overall survival as the endpoint. (RACONTEUR)